HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $38.
July 10, 2023 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iovance Biotherapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $38.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Iovance Biotherapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100